In recent years, a growing volume of disciplined medical research has emerged regarding the use of medical cannabis as a treatment method for conditions allowed under the Texas Compassionate Use Program: Epilepsy and other seizure disorders, autism spectrum disorder, multiple sclerosis and spasticity, cancer and palliative care, and neurodegenerative diseases.

This research, coupled with an increasing volume of positive results, has led to expanded interest among patients and growing receptivity among physicians for the use of medical marijuana as a part of their prescription regimes.

Explore the research for some of the covered conditions below. Within each condition, you will be able to browse a variety of current research and clinical trials. We are always updating our library of research.

Epilepsy and Other Seizure Disorders

In the case of epilepsy, new medications are desperately needed as 30%–40% of people with epilepsy do not respond to traditional medication regimens. There is also a great deal of concern from patients and their families about the long-term effects of chronic anti-epilepsy drug use.

Fortunately, multiple randomized, placebo-controlled trials indicate both the safety and efficacy of medical cannabis for the treatment of epilepsy.


Epilepsy Symptoms Recommended Formulations

  • SEIZURES | High-CBD Formulation
  • ANXIETY High-CBD Formulation

Seizure Management Resources

  • Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome  |  Read More
  • Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome: a randomized, double-blind, placebo-controlled phase 3 trial  |  Read More
  • Effect of Cannabidiol on drop seizures in the Lennox-Gastaut Syndrome  |  Read More

Other Epilepsy Resources 

  • Perceived Efficacy Of Cannabidiol-enriched Cannabis Extracts For Treatment Of Pediatric Epilepsy  |  Read More
  • Cannabinoids and Epilepsy  |  Read More
  • CBD-enriched Medical Cannabis For Intractable Pediatric Epilepsy  |  Read More
  • Efficacy Of Artisanal Preparations Of Cannabidiol For The Treatment Of Epilepsy  |  Read More
  • Efficacy Of CBD-enriched Medical Cannabis For Treatment Of Refractory Epilepsy In Children  |  Read More

Multiple Sclerosis

Recent studies indicate there is expanding acceptance of cannabis within the MS community. While there are many uncertainties about the overall effects associated with cannabis use in patients with MS, research shows cannabis strains, containing CBD levels equal or higher than THC, have had positive effects on muscle spasticity and pain. The effects of medical marijuana, and its safety, have been  reviewed by the American Academy of Neurology in a practice guideline. 


Multiple Sclerosis Recommended Formulations

  • ANXIETY | High-CBD Formulation
  • PAIN Balanced Formulation
  • MUSCLE SPASM Balanced Formulation

Clinical Trial Results

  • Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial  |  Read More
  • Randomized Controlled Trials of Cannabis-Based Medicine in Spasticity Caused by Multiple Sclerosis  |  Read More
  • Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis  |  Read More
  • Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients​.  |  Read More


Access to medical cannabis use for the treatment of Autism Spectrum Disorder (ASD) symptoms was preceded by treatment of epilepsy symptoms. Research showed the initial use by patients with epilepsy had improvement in anxiety, aggression, panic, tantrums, and self-injurious behaviors. This caused parents of children with ASD to seek out cannabis treatment in hopes of achieving the same results.


Autism Symptoms Recommended Formulations

  • DEPRESSION | High-CBD Formulation
  • SEIZURES High-CBD Formulation
  • RESTLESSNESS | High-CBD Formulation
  • INSOMNIA Balanced Formulation
  • TICS | Balanced Formulation

Human-Based Clinical Trial Results

  • Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities  |  Read More
  • Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasibility Study  |  Read More
  • Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy  |  Read More
  • ​Ethical Implications for Providers Regarding Cannabis Use in Children With Autism Spectrum Disorders​  |  Read More

Terminal Cancer

There is an increased interest in the use of cannabinoids in the treatment of symptoms in cancer and palliative care patients, including pain, loss of appetite, anxiety, insomnia and nausea. In 2016, The American Society of Clinical Oncology published guidelines to help cancer survivors manage chronic pain. These recommendations included the use of medical marijuana and cannabinoid-based medicines. 

Terminal Cancer Symptoms Recommended Formulations
  • ANXIETY | High-CBD Formulation
  • PAIN | Balanced Formulation
  • APPETITE LOSS Balanced Formulation
  • INSOMNIA | Balanced Formulation
  • NAUSEA | Balanced Formulation

Clinical Trial Results

  • Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain  |  Read More
  • An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics  |  Read More

Human Trial Results

  • Patterns of Use of Medical Cannabis Among Israeli Cancer Patients: A Single Institution Experience  |  Read More

Other Articles of Interest

  • Cannabinoids as therapeutic agents in cancer: current status and future implications  |  Read More
  • Cannabis in palliative care: current challenges and practical recommendations  |  Read More
  • Choice of opioids and the WHO ladder  |  Read More
  • Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis  |  Read More
  • Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review  |  Read More
  • Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline  |  Read More
  • Patterns of Use of Medical Cannabis Among Israeli Cancer Patients: A Single Institution Experience  |  Read More
  • Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer  |  Read More


Some studies indicate use of medical cannabis slows the progress of neurodegeneration. Medical marijuana may improve the quality of life for individuals with amyotrophic lateral sclerosis symptoms by improving appetite and sleep, while decreasing pain and spasticity.


ALS Symptoms Recommended Formulations

  • APPETITE LOSS High-CBD Formulation & Balanced Formulation
  • PAIN | Balanced Formulation
  • SPASTICITY | Balanced Formulation

Clinical Trial Results

  • Survey of cannabis use in patients with amyotrophic lateral sclerosis |  Read More

Other Articles of Interest

  • Cannabis and ALS: Hypothetical and Practical Applications, and a Call for Clinical Trials   |  Read More
  • Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?   |  Read More
  • Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders   |  Read More
  • Endocannabinoids and amyotrophic lateral sclerosis   |  Read More

Research On Symptoms Related to ALS

  • Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?  |  Read More
  • Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors  |  Read More
  • Randomized Controlled Trials of Cannabis-Based Medicine in Spasticity Caused by Multiple Sclerosis  |  Read More
  • Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial  |  Read More
  • Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis  |  Read More


Alzheimer’s disease is a complex age-related neurodegenerative disease characterized by the progressive loss of memory and cognitive function. Approximately 36 million people worldwide suffer from Alzheimer’s disease, a number estimated to triple by 2050. Alzheimer’s disease often leads to death within 3 to 9 years. Pharmacological modulation of the endocannabinoid system is emerging as a viable therapeutic target for the treatment of Alzheimer’s disease. Symptoms of Alzheimer’s disease that may respond positively to medical cannabis treatments include sleep problems, paranoia, anxiety, dysphoria, pain, poor appetite, and weight loss. In late stage Alzheimer’s, cannabis may improve appetite, sleep issues, and diminish agitation.


Alzheimer’s Disease Symptoms Recommended Formulations

  • APPETITE LOSS Balanced Formulation
  • INSOMNIA/SLEEP ISSUES Balanced Formulation
  • MEMORY LOSS Balanced Formulation
  • PAIN Balanced Formulation

Clinical Trial Results

  • Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease  |  Read More
  • Delta9-tetrahydrocannabinol for nighttime agitation in severe dementia  |  Read More
  • Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study  |  Read More

Human Trial Results

  • The Potential Therapeutic Effects of THC on Alzheimer’s Disease  |  Read More

Other Articles of Interest

  • Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids  |  Read More
  • Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders  |  Read More
  • The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation  |  Read More
  • THC for age-related cognitive decline?  |  Read More
  • Cannabinoids remove plaque-forming Alzheimer’s proteins from brain cells  |  Read More
  • Alzheimer’s disease; taking the edge off with cannabinoids?  |  Read More
  • Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic  |  Read More
  • A Molecular Link Between the Active Component of Marijuana and Alzheimer’s Disease Pathology  |  Read More
  • Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors  |  Read More


Parkinson’s disease (PD) is a progressive neurodegenerative disorder involving the nigrostriatal motor circuits of the basal ganglia. Average age of diagnosis is around 60, but most patients have already lost more than half of the dopaminergic neurons in the affected circuitry at diagnosis. Cardinal symptoms of PD include resting tremor, muscular rigidity, bradykinesia and postural instability.  Associated symptoms can include depression, anxiety, hallucinations, sleep disorders, and late-stage dementia. All current therapies for PD are symptomatic, and are fraught with detrimental side effects in the form of treatment-associated dyskinesias that limit benefit. Meanwhile, the search for a neuroprotective therapy continues, seeking a treatment that might prevent or slow progression. Extensive preclinical studies in animal models of PD provide evidence that modulation of the endocannabinoid system may impact these various aspects of PD, as summarized by Concannon et al. Cannabinoid receptors are present in high density in the basal ganglia tissues involved in PD. Multiple studies in animal models have demonstrated symptom relief, amelioration of treatment-induced dyskinesias, and suggest a role in neuroprotection with various cannabinoid therapies.

Evidence from human clinical trials remains limited to early trials, mostly observational with small volumes of patients. Self-reported outcomes have often included favorable reports of efficacy, while a very limited number of controlled trials have not reproduced those findings. Babayeva et al provides an excellent summary of multiple small PD studies of mobility, dyskinesia amelioration, and associated symptoms including pain, anxiety, sleep and depression. Some studies have yielded conflicting results, and more research is necessary to clarify the specific benefits of medical cannabis for PD to allow more comprehensive future evaluation of best practices for treatment.


Parkinson’s Disease Symptoms Recommended Formulations

  • INSOMNIA/SLEEP ISSUES Balanced Formulation
  • MUSCLE SPASMS Balanced Formulation
  • PAIN Balanced Formulation
  • TREMORS Balanced Formulation

Double-Blind, Randomized, Placebo-Controlled Studies

  • Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial  |  Read More

Other Research of Interest

  • Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study  |  Read More
  • Marijuana for Parkinson’s Disease?; Innovations in Clinical Science  |  Read More
  • Marijuana Compounds: A Nonconventional Approach to Parkinson’s Disease Therapy  |  Read More
  • Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms  |  Read More
  • Cannabis use in people with Parkinson’s disease and Multiple Sclerosis: A web-based investigation  |  Read More
  • Cannabinoids in Parkinson’s disease. Cannabinoids in Neurologic and Mental Disease  |  Read More
  • Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection  |  Read More

Are we missing valuable research or articles? Want to contribute to our resources?

Schedule a Free Consultation



Get updates on our products, qualifying conditions, the medical cannabis industry, and more.